keyword
MENU ▼
Read by QxMD icon Read
search

Cardioverter defibrillator

keyword
https://www.readbyqxmd.com/read/29440186/long-term-outcome-of-substrate-modification-in-ablation-of-post-myocardial-infarction-ventricular-tachycardia
#1
Michael Wolf, Frédéric Sacher, Hubert Cochet, Takeshi Kitamura, Masateru Takigawa, Seigo Yamashita, Konstantinos Vlachos, Ghassen Cheniti, Antonio Frontera, Ruairidh Martin, Nathaniel Thompson, Grégoire Massoullié, Anna Lam, Claire Martin, Florent Collot, Josselin Duchateau, Thomas Pambrun, Arnaud Denis, Nicolas Derval, Mélèze Hocini, Michel Haïssaguerre, Pierre Jaïs
BACKGROUND: Long-term results of substrate modification for ablation of ventricular tachycardia (VT) have not been reported. We report long-term outcomes of substrate elimination targeting local abnormal ventricular activities (LAVA) for post-myocardial infarction VT. METHODS AND RESULTS: One hundred fifty-nine consecutive patients undergoing first ablation were included (65±11 years, 92% implantable cardioverter defibrillators, 54% storms, and 73% appropriate shocks)...
February 2018: Circulation. Arrhythmia and Electrophysiology
https://www.readbyqxmd.com/read/29437742/implantable-cardioverter-defibrillators-in-the-context-of-hypertrophic-cardiomyopathy-a-lesson-in-patient-autonomy
#2
Jonathan James Hyett Bray, Chiara Bucciarelli-Ducci, Graham Stuart
Hypertrophiccardiomyopathy (HCM) is common, whereas the decision not to have an implantable cardioverterdefibrillator (ICD) when probably falling into a 'high-risk' category is not. A solicitor aged 45 years attended the inherited cardiac conditions clinic for review of her HCM and discussion about ICD implantation for primary prevention of sudden cardiac death (SCD). Despite a predicted 7% risk of SCD within the next 5 years, according to the European Society of Cardiology endorsed HCM Risk-SCD risk stratification tool, the patient opted against implantation of an ICD and comprehensively justifies her decision...
February 5, 2018: BMJ Case Reports
https://www.readbyqxmd.com/read/29435656/-management-of-inappropriate-shocks-t-wave-oversensing-in-s-icd%C3%A2-patients
#3
REVIEW
Robert Larbig, Markus Bettin, Lukas J Motloch, Alicia Fischer, Niklas Bode, Gerrit Frommeyer, Florian Reinke, Andreas Loeher, Lars Eckardt, Julia Köbe
Inappropriate shocks are a feared complication after implantable cardioverter-defibrillator (ICD) implantation and have a tremendous impact on quality of life. Inappropriate shocks in patients with subcutaneous ICD (S-ICD®, Boston Scientific, Marlborough, MA, USA) have various underlying causes. This review summarizes the current literature on this topic and lists possible treatment options.
February 12, 2018: Herzschrittmachertherapie & Elektrophysiologie
https://www.readbyqxmd.com/read/29432525/factors-influencing-the-use-of-subcutaneous-or-transvenous-implantable-cardioverter-defibrillators-results-of-the-european-heart-rhythm-association-prospective-survey
#4
Serge Boveda, Radoslaw Lenarczyk, Stefano Fumagalli, Roland Tilz, Kinga Goscinska-Bis, Maciej Kempa, Pascal Defaye, Christelle Marquié, Alessandro Capucci, Laura Ueberham, Nikolaos Dagres
The purpose of this European Heart Rhythm Association (EHRA) prospective snapshot survey is to provide an overview of the factors influencing patient selection for the implantation of a particular type of device: subcutaneous implantable cardioverter-defibrillator (S-ICD) or transvenous implantable cardioverter-defibrillator (TV-ICD), across a broad range of tertiary European centres. A specially designed electronic questionnaire was sent via the internet to tertiary reference centres routinely implanting both TV-ICDs and S-ICDs...
February 8, 2018: Europace: European Pacing, Arrhythmias, and Cardiac Electrophysiology
https://www.readbyqxmd.com/read/29431527/role-of-cardiac-electronic-implantable-device-in-the-stratification-and-management-of-embolic-risk-of-silent-atrial-fibrillation-are-all-atrial-fibrillations-created-equal
#5
Andrea Di Cori, Alessio Lilli, Giulio Zucchelli, Valerio Zaca
Ischemic strokes may be associated with atrial fibrillation (AF). AF detection is critical in ischemic stroke survivors, often recommending a switch from antiplatelet therapy to oral anticoagulants for secondary prevention. Areas covered: Cardiac implantable electronic devices (CIED) with their long-term recording capability allows to document AF and to quantify the arrhythmia burden. Recent series in pacemaker and implantable cardioverter-defibrillator (ICD) recipients with no prior stroke showed that short episodes of AF increased stroke risk compared with those without AF recorded...
February 12, 2018: Expert Review of Cardiovascular Therapy
https://www.readbyqxmd.com/read/29431384/cardiomyopathy-an-overview
#6
Jay Brieler, Matthew A Breeden, Jane Tucker
The definition and classification of cardiomyopathy have evolved considerably in recent years. Cardiomyopathy can be separated into primary (genetic, mixed, or acquired) and secondary categories, which result in varied phenotypes including dilated, hypertrophic, and restrictive patterns. Hypertrophic cardiomyopathy is the most common primary cardiomyopathy and can cause exertional dyspnea, presyncope, atypical chest pain, heart failure, and sudden cardiac death. Dilated cardiomyopathy can be genetic or acquired and typically presents with classic symptoms of heart failure with reduced ejection fraction...
November 15, 2017: American Family Physician
https://www.readbyqxmd.com/read/29428143/causes-and-prevention-of-inappropriate-implantable-cardioverter-defibrillator-shocks
#7
REVIEW
Nitin Kulkarni, Mark S Link
Use of implantable cardioverter-defibrillators as a primary prevention therapy has been shown to reduce mortality in patients after cardiac arrest and also with left ventricular systolic dysfunction. Yet, inappropriate shocks are variably reported and associated with a reduction in quality of life. Inappropriate shocks are the result of environmental causes leading to electromagnetic interference and inappropriate sensing of external noise, device-related causes from inappropriate sensing of physiologic or pathologic signals, and supraventricular arrhythmias...
March 2018: Cardiac Electrophysiology Clinics
https://www.readbyqxmd.com/read/29428142/should-single-coil-implantable-cardioverter-defibrillator-leads-be-used-in-all-patients
#8
REVIEW
Fahad Almehmadi, Jaimie Manlucu
The historical preference for dual-coil implantable cardioverter defibrillator leads stems from high defibrillation thresholds associated with old device platforms. The high safety margins generated by contemporary devices have rendered the modest difference in defibrillation efficacy between single- and dual-coil leads clinically insignificant. Cohort data demonstrating worse lead extraction outcomes and higher all-cause mortality have brought the incremental utility of an superior vena cava coil into question...
March 2018: Cardiac Electrophysiology Clinics
https://www.readbyqxmd.com/read/29428136/important-parameters-for-implantable-cardioverter-defibrillator-selection
#9
REVIEW
Nath Zungsontiporn, Michael Loguidice, James Daniels
The efficacy of implantable cardioverter defibrillators in reducing the risk of sudden cardiac death has been well established by several clinical trials. Several factors relating to device characteristics, patient attributes, and comorbidities should be considered when selecting the appropriate implantable cardioverter defibrillators for each patient. This review examines some of these issues.
March 2018: Cardiac Electrophysiology Clinics
https://www.readbyqxmd.com/read/29428135/when-is-it-safe-not-to-reimplant-an-implantable-cardioverter-defibrillator-at-the-time-of-battery-depletion
#10
REVIEW
Sana M Al-Khatib, Daniel J Friedman, Gillian D Sanders
The implantable cardioverter defibrillator (ICD) is a life-saving therapy in various patient populations. Although data on the outcomes of initial ICD implants are abundant, data on ICD replacements, especially in patients with improved left ventricular (LV) function, are scarce. Therefore, it is not known when it is safe to not replace an ICD that has reached the end of battery life. This article reviews data on patients with primary prevention ICDs who have improvement in left ventricular ejection fraction during follow-up and provides some guidance, based on the available evidence, related to circumstances when replacement of an ICD may be forgone...
March 2018: Cardiac Electrophysiology Clinics
https://www.readbyqxmd.com/read/29428133/implantable-cardioverter-defibrillator-implantation-with-or-without-defibrillation-testing
#11
REVIEW
Stephen Duffett, Imane El Hajjaji, Jaimie Manlucu, Raymond Yee
Defibrillation testing (DFT) during implantable cardioverter-defibrillator (ICD) implantation is still considered standard of care in some, but in increasingly fewer centers. The goal is to ensure that the device system functions as intended by testing in the controlled laboratory setting. Although safe, complications can occur and DFT is associated with an increased procedural time and cost. DFT is useful in assessing device function when programming changes or patient characteristics raise concerns regarding ICD efficacy...
March 2018: Cardiac Electrophysiology Clinics
https://www.readbyqxmd.com/read/29428131/use-of-the-wearable-cardioverter-defibrillator-as-a-bridge-to-implantable-cardioverter-defibrillator
#12
REVIEW
Jonathan Weinstock
The wearable cardioverter defibrillator has been shown to be effective in terminating ventricular arrhythmias in patients at risk for sudden cardiac death. There are numerous scenarios in which implant of a permanent implantable cardioverter defibrillator is temporarily contraindicated or not advisable and a wearable cardioverter defibrillator may be beneficial. There are no prospective randomized studies published that provide conclusive guidance toward the use of the wearable cardioverter defibrillator, and thus, patient management needs to be individualized based on the available data...
March 2018: Cardiac Electrophysiology Clinics
https://www.readbyqxmd.com/read/29425546/prognostic-impact-of-electrical-storm-in-patients-with-implantable-cardioverter-defibrillators-mechanistic-and-therapeutic-considerations-to-reduce-the-risk-of-death
#13
EDITORIAL
Yukiomi Tsuji, Dobromir Dobrev
No abstract text is available yet for this article.
March 15, 2018: International Journal of Cardiology
https://www.readbyqxmd.com/read/29422952/gender-differences-in-the-use-of-primary-prevention-icds-in-new-zealand-patients-with-heart-failure
#14
Khang-Li Looi, Karishma Sidhu, Lisa Cooper, Liane Dawson, Debbie Slipper, Andrew Gavin, Nigel Lever
Objective: Women have been under-represented in randomised clinical trials for primary prevention implantable cardioverter defibrillators (ICDs), and there are concerns about the efficacy of devices between genders. Our study aimed to investigate gender differences in the use of primary prevention ICD in patients with heart failure from the northern region of New Zealand. Methods: Patients with heart failure with systolic dysfunction who received primary prevention ICD/cardiac resynchronisation therapy-defibrillator (CRT-D) in the northern region of New Zealand from 1 January 2007 to 1 June 2015 were included...
2018: Heart Asia
https://www.readbyqxmd.com/read/29419707/assessing-variation-in-implantable-cardioverter-defibrillator-therapy-guideline-adherence-with-physician-and-hospital-patient-sharing-networks
#15
Erika L Moen, Julie P Bynum, Andrea M Austin, Jonathan S Skinner, Gouri Chakraborti, Alistair James O'Malley
BACKGROUND: Implantable cardioverter defibrillator (ICD) therapy is used for primary prevention of death among people with heart failure, and new evidence in 2005 on its effectiveness changed practice guidelines in the United States. OBJECTIVES: The objective of this study is to examine how the connectedness of physicians and hospitals, measured using network analysis, relates to guideline-consistent ICD implantation. RESEARCH DESIGN: We constructed physician and hospital networks for cardiovascular disease...
February 6, 2018: Medical Care
https://www.readbyqxmd.com/read/29414264/risk-stratification-for-sudden-cardiac-death-after-myocardial-infarction
#16
Jonathan W Waks, Alfred E Buxton
Sudden cardiac death (SCD) accounts for ∼50% of mortality after myocardial infarction (MI). Most SCDs result from ventricular tachyarrhythmias, and the tachycardias that precipitate cardiac arrest result from multiple mechanisms. As a result, it is highly unlikely that any single test will identify all patients at risk for SCD. Current guidelines for use of implantable cardioverter-defibrillators (ICDs) to prevent SCD are based primarily on measurement of left ventricular ejection fraction (LVEF). Although reduced LVEF is associated with increased total cardiac mortality after MI, the focus of current guidelines on LVEF omits ∼50% of patients who die suddenly...
January 29, 2018: Annual Review of Medicine
https://www.readbyqxmd.com/read/29414256/updated-recommendations-for-athletes-with-heart-disease
#17
Rachel Lampert, Douglas P Zipes
Professional society recommendations to decrease sudden cardiac death in athletes, including eligibility requirements with disqualification for athletes with diagnosed disease as well as preparticipation screening and emergency preparedness, were updated in 2015. The update includes new sections on aortic disease, channelopathies, and sickle cell trait, as well as a change in format from the previous binary yes/no format to the more nuanced and contemporary "class and level of evidence" format. Eighty-four of the 246 recommendations now carry Class II designation-"reasonable," or "may be considered...
January 29, 2018: Annual Review of Medicine
https://www.readbyqxmd.com/read/29411719/gender-differences-and-demographics-and-type-of-cardiac-device-over-a-10-year-period
#18
M Aktoz, M F Uçar, M A Yılmaztepe, G Taylan, S Altay
AIMS: This study aims to review the influence of gender-specific differences and patient demographics on cardiac device and pacing mode selection over a 10-year period. METHODS: We retrospectively reviewed patients who underwent first implantation of the cardiac device between January 1, 2006 and June 31, 2016. RESULTS: During the study period, 704 patients underwent first cardiac device implantation. Number of patients undergoing pacemaker was 452 and number of patients undergoing implantable cardioverter defibrillator/cardiac resynchronization therapy and defibrillator (ICD/CRT-D) was 252...
January 2018: Nigerian Journal of Clinical Practice
https://www.readbyqxmd.com/read/29408436/predicting-arrhythmic-risk-in-arrhythmogenic-right-ventricular-cardiomyopathy-a-systematic-review-and-meta-analysis
#19
Laurens P Bosman, Arjan Sammani, Cynthia A James, Julia Cadrin-Tourigny, Hugh Calkins, J Peter van Tintelen, Richard N W Hauer, Folkert W Asselbergs, Anneline S J M Te Riele
While many studies evaluate predictors for ventricular arrhythmias in Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC), a systematic review consolidating this evidence is currently lacking. Therefore, we searched MEDLINE and Embase for studies analyzing predictors for ventricular arrhythmias (sustained ventricular tachycardia/fibrillation (VT/VF), appropriate implantable cardioverter-defibrillator therapy, or sudden cardiac death) in definite ARVC patients, borderline ARVC patients, and ARVC-associated mutation carriers...
February 2, 2018: Heart Rhythm: the Official Journal of the Heart Rhythm Society
https://www.readbyqxmd.com/read/29407088/programmed-ventricular-stimulation-predicts-arrhythmic-events-and-survival-in-hypertrophic-cardiomyopathy
#20
Konstantinos A Gatzoulis, Stavros Georgopoulos, Christos-Konstantinos Antoniou, Aris Anastasakis, Polychronis Dilaveris, Petros Arsenos, Skevos Sideris, Dimitris Tsiachris, Stefanos Archontakis, Elias Sotiropoulos, Artemisia Theopistou, Ioannis Skiadas, Ioannis Kallikazaros, Christodoulos Stefanadis, Dimitrios Tousoulis
BACKGROUND: Sudden cardiac death (SCD) risk stratification in hypertrophic cardiomyopathy (HCM) in the context of primary prevention remains suboptimal. The purpose of this study was to examine the additional contribution of programmed ventricular stimulation (PVS) on established risk assessment. METHODS: Two-hundred-and-three consecutive patients with diagnosed HCM and ≥1 noninvasive risk factors were prospectively enrolled over 19years. Patients were risk stratified, submitted to PVS and received an implantable cardioverter-defibrillator (ICD) according to then-current American Heart Association (AHA) guidelines and inducibility...
March 1, 2018: International Journal of Cardiology
keyword
keyword
38447
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"